Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
29/05/2026 09:21
BRIEF-Xintela Study Finds XSTEM Treatment Safe, Well Tolerated May 29 (Reuters) - Xintela AB XINT.ST:
ONE DOSE OF XSTEM FOUND SAFE AND WELL TOLERATED IN PHASE I/IIA STUDY
Source text: ID:nMFN1xCN2s
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects